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ABSTRACT 
 
The aim of this study was to determine the efficacy of the combination of Nigersan® 4X, 
Citrokehl® 10X/30X/200X and Recarcin® 4X in the treatment of symptoms experienced 
with endometriosis. Endometriosis is a gynaecological disorder, where functioning 
endometrial tissue is present outside the uterine cavity. Symptoms are often associated 
with severe pain and/or infertility. The aetiology is unknown and there is no cure for 
endometriosis.  
 
This was a double blind study in which a placebo group was compared to an experimental 
group. Twenty five females with pre-diagnosed endometriosis were analysed over a twelve 
week period. The participants were randomly divided into two groups, one receiving 
Nigersan® 4X, Citrokehl® 10X/30X/200X and Recarcin® 4X and the other placebo. This 
was a subjective study with reference to the participant’s perception of their condition 
before, during and at the end of the study. Participants were asked to record the following 
on a daily basis: menstruation, pelvic pain, backache, nausea, vomiting and diarrhoea. The 
participants were then also asked to rate the following on a monthly basis: energy levels, 
general wellbeing, dysmenorrhea, pelvic pain, menstrual clotting, menstrual flow, menstrual 
colour and dyspareunia. All forms and questionairres were then collected at four week 
intervals and analysed for comparison. 
 
The data was statistically analysed using the Analysis of Variance technique and Chi-
squared statistics. Results revealed a significant decrease in the average number of days 
of backache and pelvic pain within the placebo group while the experimental group 
indicated a significant improvement in energy levels and general wellbeing.   
 
Therefore it is concluded that Nigersan® 4X, Citrokehl® 10X/30X/200X and Recarcin® 4X 
did not significantly alleviate symptoms associated with endometriosis.    
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